Page last updated: 2024-08-22

platinum and Cancer of the Fallopian Tube

platinum has been researched along with Cancer of the Fallopian Tube in 19 studies

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (5.26)18.2507
2000's0 (0.00)29.6817
2010's10 (52.63)24.3611
2020's8 (42.11)2.80

Authors

AuthorsStudies
Altwerger, G; Andikyan, V; Azodi, M; Bellone, S; Buza, N; Clark, M; Harold, J; Huang, GS; Hui, P; Mauricio, D; Menderes, G; Rao, GG; Ratner, E; Reader, JC; Roque, DM; Santin, AD; Schwartz, PE; Siegel, ER; Silasi, DA; Tymon-Rosario, JR; Zeybek, B1
Benjamin, L; Corr, BR; Culm-Merdek, K; Fu, S; Hamilton, EP; Mockbee, C; Moore, KN; Naumann, RW; Rosengarten, RD; Stagg, R; Wenham, RM; Youssoufian, H1
Abe, M; Aida, T; Baba, T; Kagabu, M; Kaido, Y; Nagasawa, T; Shoji, T; Takatori, E; Tatsuki, S; Tomabechi, H1
Baba, T; Furukawa, S; Kagabu, M; Kaiho-Sakuma, M; Matsumura, Y; Nagasawa, T; Nagase, S; Ohta, T; Seino, M; Shigeta, S; Shigeto, T; Shimada, M; Shimizu, D; Shoji, T; Soeda, S; Takahashi, F; Takatori, E; Terada, Y; Tokunaga, H; Watanabe, T; Yokoyama, Y1
Hamontri, S; Tantitamit, T1
Goto, M; Hori, K; Ito, K; Onoue, M; Takaki, E; Takei, T; Tashima, L; Tsuji, S; Yamashita, M; Yoshioka, E1
Alvarez, N; Colombo, N; dePont Christensen, R; Gonzalez Martin, A; Heitz, F; Marqués, C; Meirovitz, M; Sanchez Lorenzo, L; Sanchez, J; Selle, F; van Gorp, T1
Adorno-Cruz, V; Berry, E; Cowan, M; Kocherginsky, M; Lurain, JR; Matei, D; Nelson, V; Neubauer, NL; O'Shea, KL; Pineda, MJ; Shahabi, S; Swetzig, WM; Taiym, D1
Fujiwara, H; Hamano, T; Itamochi, H; Kamiura, S; Kato, K; Kigawa, J; Komiyama, S; Shoji, T; Sugiyama, T; Tanabe, H1
Butow, P; Donovan, H; Friedlander, ML; Gillies, K; King, MT; Martyn, J; O'Connell, R; Oza, A; Sjoquist, K; Stockler, M; Voysey, M1
Banerjee, S; Clamp, A; Dawson-Athey, L; Earl, H; Feeney, A; Hall, G; Hall, M; James, L; Kaye, SB; Khan, I; Kristeleit, R; Lawrence, C; Ledermann, JA; McNeish, IA; Persic, M; Raja, F; Webber, L1
Berton-Rigaud, D; Fabbro, M; Favier, L; Lesoin, A; Lortholary, A; Mari, V; Pujade-Lauraine, E; Ray-Coquard, I; Selle, F; Sevin, E1
Ganovska, A; Kovachev, S1
Allen, AR; Bell-McGuinn, KM; Brenton, JD; Coleman, RL; Cragun, JM; Floquet, A; Giordano, H; Goble, S; Harding, TC; Harrell, MI; Isaacson, J; Kaufmann, SH; Konecny, GE; Kristeleit, RS; Leary, A; Lin, KK; Ma, L; Maloney, L; Mann, E; McNeish, IA; O'Malley, DM; Oaknin, A; Oza, AM; Raponi, M; Ray-Coquard, I; Rolfe, L; Scott, CL; Sun, J; Swisher, EM; Tinker, AV; Yelensky, R1
Barbieri, P; Brienza, S; Carminati, P; Colombo, N; du Bois, A; Frigerio, L; Guastalla, JP; Katsaròs, D; Lhommé, C; Lissoni, AA; Parma, G; Pecorelli, S; Poveda, A; Ray-Coquard, I; Tisi, G; Tredan, O; Vermorken, JB1
Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK1
Arimoto, T; Kawana, K; Nakagawa, S; Oda, K; Taketani, Y; Yasugi, T1
Arnold, AG; Grisham, RN; Hyman, DM; Iasonos, A; Kauff, ND; Spriggs, D; Zhou, Q1
Crowther, D; Lind, MJ; McAuliffe, CA; Murphy, DJ; Sharma, H; Smith, A; Tinker, N1

Trials

9 trial(s) available for platinum and Cancer of the Fallopian Tube

ArticleYear
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
    British journal of cancer, 2022, Volume: 126, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Epothilones; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum

2022
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 08-10, Volume: 40, Issue:23

    Topics: Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; RNA; Tumor Microenvironment; Vascular Endothelial Growth Factor A

2022
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2021, Volume: 31, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Peritoneal Neoplasms; Piperidines; Platinum; Progression-Free Survival; Time Factors

2021
Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial.
    Gynecologic oncology, 2021, Volume: 163, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Platinum; Quinolines

2021
An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizuma
    BMC cancer, 2018, Jul-31, Volume: 18, Issue:1

    Topics: Antineoplastic Agents; Bevacizumab; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Progression-Free Survival

2018
A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Disease-Free Survival; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Quinazolines; Retroperitoneal Neoplasms

2014
A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Humans; Lenalidomide; Membrane Proteins; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Thalidomide

2014
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
    The Lancet. Oncology, 2017, Volume: 18, Issue:1

    Topics: Aged; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Germ-Line Mutation; Humans; Indoles; International Agencies; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate

2017
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Recurrence; Taxoids

2010

Other Studies

10 other study(ies) available for platinum and Cancer of the Fallopian Tube

ArticleYear
Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study.
    Anticancer research, 2022, Volume: 42, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Retrospective Studies

2022
Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study).
    International journal of clinical oncology, 2022, Volume: 27, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Progression-Free Survival; Retrospective Studies

2022
Outcomes and Prognostic Factors of Patients with Platinum- Resistant or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2023, Apr-01, Volume: 24, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prognosis

2023
[Efficacy of Olaparib Treatment for Platinum-Sensitive Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancers].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:10

    Topics: Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum

2020
Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Palliative Care; Peritoneal Neoplasms; Platinum; Prognosis; Quality of Life; Severity of Illness Index; Surveys and Questionnaires

2014
[The primary cancer of fallopian tube--a clinical case].
    Akusherstvo i ginekologiia, 2015, Volume: 54, Issue:8

    Topics: Aged; Antineoplastic Agents; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Hysterectomy; Platinum; Taxoids

2015
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome

2011
Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome

2012
Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers.
    Gynecologic oncology, 2011, Volume: 123, Issue:2

    Topics: Adult; Aged; Disease-Free Survival; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Humans; Middle Aged; Mutation; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Retrospective Studies; Topoisomerase I Inhibitors; Topotecan

2011
Comparative intraperitoneal pharmacokinetics of three platinum analogues.
    Cancer chemotherapy and pharmacology, 1991, Volume: 28, Issue:4

    Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Radioisotopes; Time Factors

1991